Evidence map›Paper›PMID 41388125›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

NAD⁺ Reduction in Glutamatergic Neurons Induces Lipid Catabolism and Neuroinflammation in the Brain via SARM1.

Zhen-Xian Niou, Sen Yang, Andrea Enriquez, Nino A Espinas, Anoosha Sri, Caliel D Hines, Jason M Tennessen, Chia-Shan Wu, Jui-Yen Huang, Hui-Chen Lu

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. WTAP-Mediated mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

  • Update of
    NAD2025
5 · Who and what money

Authors and funding

10 authors.

Zhen-Xian NiouGill Institute for Neuroscience, Indiana University, Bloomington, USA.ORCID https://orcid.org/0000-0002-4683-1964
Sen YangGill Institute for Neuroscience, Indiana University, Bloomington, USA.
Andrea EnriquezGill Institute for Neuroscience, Indiana University, Bloomington, USA.
Nino A EspinasGill Institute for Neuroscience, Indiana University, Bloomington, USA.
Anoosha SriGill Institute for Neuroscience, Indiana University, Bloomington, USA.
Caliel D HinesGill Institute for Neuroscience, Indiana University, Bloomington, USA.
Jason M TennessenDepartment of Biology, Indiana University, Bloomington, USA.
Chia-Shan WuDepartment of Nutrition, Texas A&M University, College Station, USA.
Jui-Yen HuangGill Institute for Neuroscience, Indiana University, Bloomington, USA.
Hui-Chen LuGill Institute for Neuroscience, Indiana University, Bloomington, USA.ORCID https://orcid.org/0000-0002-6628-7177

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Multi-Scale Imaging Core (MSIC)P30DA056410 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Kenneth Mackie · 2023 to 2026
$7.1M
Molecular and genetic studies of NMNAT2 in neuroprotectionR01NS086794 · NINDS · TRUSTEES OF INDIANA UNIVERSITY · PI LU, HUI-CHEN · 2014 to 2025
$5.0M
Agilent 6550 QTOF system for U of UtahS10OD016232 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2013 to 2013
$578k
Q-ToF Mass Spectrometer for the University of Utah MS and Proteomics CoreS10OD018210 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2015 to 2015
$530k
Agilent 7200 GC/Q-TOF for the University of UtahS10OD021505 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2016 to 2016
$401k
NCATS NIH HHS UL1 TR002529NCI NIH HHS P30 CA082709NCI NIH HHS P30CA082709NIDA NIH HHS P30 DA056410NIH HHS 1S10OD016232-01NIH HHS 1S10OD018210-01A1NIH HHS 1S10OD021505-01NIH HHS P30DA056410NIH HHS R01NS086794NIH HHS S10 OD016232NIH HHS S10 OD018210NIH HHS S10 OD021505NIH HHS UL1TR002529NINDS NIH HHS R01 NS086794
6 · The paper itself

Abstract

NAD⁺ homeostasis is vital for neuronal health, as demonstrated by the opposing roles of nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2), a NAD⁺-synthesizing enzyme, and sterile alpha and TIR motif-containing protein 1 (SARM1), a NAD⁺ hydrolase. Neurodegenerative insults that decrease NMNAT2 activate SARM1, leading to axon loss. To understand how the NMNAT2-SARM1 axis influences brain energy metabolism, multi-omics approaches are used to investigate the metabolic changes resulting from neuronal NMNAT2 loss. Loss of NMNAT2 in glutamatergic neurons leads to a significant metabolic shift in the cerebral cortex from glucose to lipid catabolism, reduced lipid abundance, and pronounced neurodegenerative phenotypes and motor behavioral deficits. These metabolic disturbances are accompanied by altered glial expression of enzymes regulating glucose and lipid metabolism, enhanced inflammatory signaling, and disrupted astrocytic transcriptomic profiles related to cholesterol synthesis and immune activation. Notably, SARM1 deletion in NMNAT2-deficient mice restored lipid metabolism, astrocyte transcriptomic profiles, and mitigated neurodegeneration and motor behaviors. These findings suggest that neuronal NAD⁺ depletion triggers maladaptive, SARM1-dependent metabolic reprogramming, shifting energy use from glucose to lipids, which in turn promotes inflammation and neurodegeneration.

Indexed as

Armadillo Domain ProteinsBrainCytoskeletal ProteinsLipid MetabolismNADNeuroinflammatory DiseasesNeuronsAnimalsMiceMice, KnockoutNicotinamide-Nucleotide AdenylyltransferaseArmadillo Domain ProteinsCytoskeletal ProteinsNADNicotinamide-Nucleotide AdenylyltransferaseNmnat2 protein, mouseSARM1 protein, mouseenergy metabolisminflammationlipidsneurodegenerationNMNAT2, SARM1

Identifiers

PMID41388125
PMCPMC12866834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.